Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, kidney, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue specimens worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was founded in 1989 and is headquartered in Oldsmar, Florida.
Industry, Sector and Symbol
Industry Services, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Phone813-749-2100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$29.22 million
Profitability
Miscellaneous
Employees92
Next Earnings Date10/21/2019 (Estimated)
OptionableNot Optionable
CRYO-CELL International (OTCMKTS:CCEL) Frequently Asked Questions
What is CRYO-CELL International's stock symbol?
CRYO-CELL International trades on the OTCMKTS under the ticker symbol "CCEL."
How were CRYO-CELL International's earnings last quarter?
CRYO-CELL International, Inc. (OTCMKTS:CCEL) posted its quarterly earnings data on Monday, July, 15th. The company reported $0.01 earnings per share (EPS) for the quarter. The firm had revenue of $8.13 million for the quarter. CRYO-CELL International had a net margin of 4.57% and a negative return on equity of 20.90%. View CRYO-CELL International's Earnings History.
When is CRYO-CELL International's next earnings date?
Has CRYO-CELL International been receiving favorable news coverage?
Media coverage about CCEL stock has trended negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. CRYO-CELL International earned a news impact score of -2.9 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for CRYO-CELL International.
Who are some of CRYO-CELL International's key competitors?
Some companies that are related to CRYO-CELL International include Molecular Templates (MTEM), SeaSpine (SPNE), Pacific Smiles Group (PSQ), RTI Surgical (RTIX), HemaCare (HEMA), Genesis Healthcare (GEN), Spero Therapeutics (SPRO), Chiasma (CHMA), LogicBio Therapeutics (LOGC), Palatin Technologies (PTN), ICC Labs (ICC), Soliton (SOLY), Poxel (PXXLF), Mallinckrodt (MNK) and Athersys (ATHX).
What other stocks do shareholders of CRYO-CELL International own?
Who are CRYO-CELL International's key executives?
CRYO-CELL International's management team includes the folowing people:
- Mr. David I. Portnoy, Chairman & Co-CEO (Age 56)
- Mr. Mark L. Portnoy, Co-CEO & Director (Age 55)
- Ms. Jill M. Taymans, CFO & VP of Fin. (Age 49)
- Mr. Oleg Mikulinsky, Chief Information Officer (Age 46)
- Dr. Merri Buff Mair, Medical Director & Member of Medical & Scientific Team
Who are CRYO-CELL International's major shareholders?
CRYO-CELL International's stock is owned by many different of institutional and retail investors. Top institutional investors include Massmutual Trust Co. FSB ADV (0.29%). Company insiders that own CRYO-CELL International stock include Arthur Ellis, Brian L Sheehy, David Portnoy, Jonathan H Wheeler and Mark L Portnoy. View Institutional Ownership Trends for CRYO-CELL International.
Which institutional investors are buying CRYO-CELL International stock?
CCEL stock was bought by a variety of institutional investors in the last quarter, including Massmutual Trust Co. FSB ADV. Company insiders that have bought CRYO-CELL International stock in the last two years include Arthur Ellis, Brian L Sheehy, David Portnoy and Jonathan H Wheeler. View Insider Buying and Selling for CRYO-CELL International.
How do I buy shares of CRYO-CELL International?
Shares of CCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is CRYO-CELL International's stock price today?
One share of CCEL stock can currently be purchased for approximately $7.54.
How big of a company is CRYO-CELL International?
What is CRYO-CELL International's official website?
How can I contact CRYO-CELL International?
CRYO-CELL International's mailing address is 700 Brooker Creek Boulevard Suite 1800, Oldsmar FL, 34677. The company can be reached via phone at 813-749-2100.
MarketBeat Community Rating for CRYO-CELL International (OTCMKTS CCEL)
MarketBeat's community ratings are surveys of what our community members think about CRYO-CELL International and other stocks. Vote "Outperform" if you believe CCEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CCEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
